References: 1. Vahdatpour C, Collins D, Goldberg S. Cardiogenic shock. J Am Heart Assoc. (2019) 8:e011991. doi: 10.1161/JAHA.119.011991 2. Shaefi S, O'Gara B, Kociol RD, et al. Effect of cardiogenic shock hospital volume on mortality in patients with cardiogenic shock. J Am Heart Assoc. 2015;4(1):e001462. Published 2015 Jan 5. doi:10.1161/JAHA.114.001462 3. A. Subramaniam, et al. Complications of Temporary Percutaneous Mechanical Circulatory Support for Cardiogenic Shock: An Appraisal of Contemporary Literature, Cardiol Ther. 2019 Dec, 8(2) 211-228.

* PercAssist internal market estimates based on incidence/growth data for cardiogenic shock and heart failure.

The PSCA technology is under development and is for investigational use only. Not yet approved by FDA and not available for commercial distribution in the United States or any other market.